Lv21
160 积分 2023-03-21 加入
The FICI paradigm: Correcting flaws in antimicrobial in vitro synergy screens at their inception
5天前
已完结
Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time
5天前
已完结
Abstract PR009: The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents
12天前
已完结
An overview of setting occupational exposure limits (OELs) for pharmaceuticals
18天前
已完结
Scientific and practical considerations for the development of occupational exposure limits (OELs) for chemical substances
18天前
已完结
Approaches for setting occupational exposure limits in the pharmaceutical industry
19天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
19天前
已完结
Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry
19天前
已完结
Phosphorous Dysregulation Induced by MEK Small Molecule Inhibitors in the Rat Involves Blockade of FGF-23 Signaling in the Kidney
1个月前
已完结
How KRAS Mutations Impair Intrinsic GTP Hydrolysis: Experimental and Computational Investigations
1个月前
已完结
皖公网安备34019202002308
